COMMENTARY

The Emerging Epidemic of Nonalcoholic Fatty Liver Disease

Rowen K. Zetterman, MD

Disclosures

January 21, 2011

In This Article

The Spectrum of Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) includes the clinical-pathologic entities of steatosis (nonalcoholic fatty liver, or NAFL) and nonalcoholic steatohepatitis (NASH) with or without fibrosis and cirrhosis.[1] Ludwig and colleagues[2] first described NASH in 1980 when they recognized a histologic pattern of fatty liver associated with lobular hepatitis, similar to alcoholic hepatitis but developing in the absence of alcoholism. Most of their patients were modestly obese and some had diabetes mellitus. NAFLD is the most frequent cause of abnormal liver tests in both adults and children.[3]

NAFLD is common.[4]The National Health and Nutrition Examination Survey (NHANES) III of American adults indicates that up to 23% may be affected.[5,6] Hepatic steatosis is more common in white men than in white women.[7,8] Hispanic whites have greater steatosis and risk for progressive liver disease than do blacks,[5] and blacks have a reduced risk for hepatic fibrosis compared with whites.[8] NAFLD also affects all ages: An autopsy study found fatty liver in nearly 10% of adolescents,[9] with boys having a greater prevalence of NAFLD than girls.[10]

Associated Diseases

Components of metabolic syndrome, including obesity, hyperlipidemia, and type 2 diabetes mellitus, are frequently present in NAFLD.[11]Metabolic syndrome is defined by the presence of truncal obesity, increased waist circumference, hyperlipidemia with elevated triglyceride and low HDL-cholesterol levels, insulin resistance with hyperglycemia, and systemic hypertension.[12] Affected patients are typically middle-aged (in their fifth decade), obese, and often more than 20% above their ideal body weight.[13] NAFLD also develops in patients of normal body weight.[14] Early cases of NASH were described following jejunoileal or jejunocolic bypass and were associated with hepatic failure and death.[15] Non-insulin-dependent diabetes mellitus (NIDDM) is present in up to 75% of cases, although diabetes mellitus is less likely in children with NASH. Morbidly obese patients presenting for gastric bypass surgery often have NAFLD and metabolic syndrome.[8]

Hyperlipidemia, rapid weight loss following gastric bypass for obesity, short bowel syndrome, prolonged use of total parenteral nutrition, small bowel bacterial overgrowth from jejunal diverticulosis, abetalipoproteinemia, hypobetalipoproteinemia, and Weber-Christian disease are associated with NAFLD[7,16] (Table 1). Lipodystrophy with fat mobilization from peripheral fat stores can result in fat accumulation and inflammation of the liver.

Table 1. Medical Conditions Associated With NAFLD

Obesity
Hyperlipidemia
Type 2 diabetes mellitus
Metabolic syndrome
Jejunoileal bypass for obesity
Jejunocolic bypass for obesity
Gastric bypass for obesity
Adult polycystic ovary syndrome
Partial limb lipodystrophy
Rapid weight loss
Short bowel syndrome
Abeta- or hypobetalipoproteinemia
Weber-Christian disease
Jejunal diverticulosis


The use of some pharmaceutical agents is also associated with NAFLD[7,17] (Table 2).

Table 2. Medications and Therapies Associated With NAFLD

Coralgil
Perhexilene maleate
Amiodarone
Thiazolidinediones (glitazones)
Total parenteral nutrition
Chloroquine
Tamoxifen
Glucocorticoids
Calcium channel blockers
Estrogens
Diethystilbestrol
Methotrexate
Thioridazine
Lamivudine
Valproic acid
Tetracyclines

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....